Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $63.40 Consensus Target Price from Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $67.8333.

Several research firms recently issued reports on ELVN. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. JonesTrading lifted their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday. The Goldman Sachs Group boosted their price target on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. HC Wainwright upped their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Finally, Stifel Nicolaus increased their price objective on Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday.

Insider Activity

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the transaction, the chief financial officer owned 51,000 shares in the company, valued at approximately $2,233,800. This represents a 10.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the sale, the director directly owned 51,884 shares in the company, valued at approximately $1,792,073.36. The trade was a 16.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Commodore Capital LP grew its position in Enliven Therapeutics by 0.4% in the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after purchasing an additional 17,809 shares during the period. Vestal Point Capital LP raised its stake in Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after buying an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc lifted its holdings in shares of Enliven Therapeutics by 13.5% during the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after buying an additional 418,673 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Enliven Therapeutics by 5.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock valued at $52,260,000 after buying an additional 142,378 shares during the period. Finally, State Street Corp boosted its stake in shares of Enliven Therapeutics by 9.1% in the 4th quarter. State Street Corp now owns 1,052,862 shares of the company’s stock worth $16,214,000 after buying an additional 87,725 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN opened at $49.82 on Friday. The firm has a market cap of $3.03 billion, a P/E ratio of -29.83 and a beta of 0.24. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $52.39. The firm has a 50-day simple moving average of $42.46 and a two-hundred day simple moving average of $33.42.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.06. On average, equities research analysts predict that Enliven Therapeutics will post -1.71 EPS for the current year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.